Abstract 5805
Background
Due to their intrinsic thermal and magnetic resonance imaging properties, magnetic nanoparticles (MNCs) have attracted more and more attention in the biomedical field. However, relatively weak photothermal conversion (PTC) efficiency and low tumor homing capacity has hampered its further application in vivo.
Methods
To solve these problems, we modified near-infrared (NIR) light-absorbing materials onto the surface of MNCs to increase PTC efficiency and increase MNCs tumor homing capacity by coated red blood cell (RBC) membranes.
Results
Our data show that after being loaded with NIR cypate molecules, the as-prepared Cyp-MNCs showed remarkably increased NIR absorbance and resultant PTC efficiency compared with the MNCs. By disguising itself, Cyp-MNCs coated with erythrocyte membranes inherit the long circulation characteristics of RBCs to improve the MNCs’ tumor homing capacity. By tracking the NIR fluorescence of cypate under an in vivo fluorescence imaging system, we discovered that such Cyp-MNC@RBCs upon intravenous injection show significantly improved tumor homing capacity compared with bare cypate-loaded MNCs. The antitumor efficiency of biomimetic Cyp-MNC@RBCs was particularly prominent and was superior to biomimetic MNC@RBCs. Additionally, fluorescence and T2-weighted magnetic resonance imaging (MRI) functionalities were all retained attributable to Cyp-MNC@RBCs cores.
Conclusions
Our study would provide a promising procedure for other similarly enhanced photothermal treatments by increasing PTC efficincies and improving tumor-homing capacity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract